Arcutis Biotherapeutics, Inc. 4

EVP & Chief Medical Officer Patrick Burnett sold 1,697 shares of Arcutis Biotherapeutics, Inc. common stock at $27.00 per share to cover RSU tax withholding, retaining 117,592 shares afterward.

On August 19, 2026, EVP and Chief Medical Officer Patrick Burnett of Arcutis Biotherapeutics, Inc. sold 1,697 shares of common stock at an indicated price of $27.00 per share, for proceeds of approximately $45,819, in a transaction explicitly disclosed as a sale solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units; following this tax-related sale, Burnett continued to hold 117,592 shares of Arcutis common stock. Given the routine, tax-withholding nature of the transaction and its moderate size, the activity appears consistent with standard equity compensation administration rather than discretionary open‑market selling.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

4

Source Type

fda

Accession

0001628280-26-058420

Alert Tier

5